User:Mr. Ibrahem/Retapamulin
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Altabax, Altargo |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a607049 |
| License data |
|
| Routes of administration | Topical (ointment) |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | Low |
| Protein binding | 94% |
| Metabolism | Liver, CYP3A4-mediated |
| Elimination half-life | Undetermined |
| Excretion | Undetermined |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C30H47NO4S |
| Molar mass | 517.77 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Retapamulin, sold as the brand name Altabax among others, is a antibiotic which is applied to the skin to threat impetigo, a bacterial skin infection.[1] It is not useful against MRSA.[1]
Common side effects include irritation at the site it is used.[1] Other side effects may include allergic reactions such as angioedema.[1] It generally works by stopping bacterial growth by inhibiting the bacterial ribosome.[1]
Retapamulin was approved for medical use in the United States and Europe in 2007.[1][2] It; however, was withdrawn from the market in 2019 in Europe.[2] In the United States 15 grams of 1% cream costs about 325 USD as of 2021.[3] It was original made from a fungus.[4]
References[edit]
- ^ a b c d e f "Retapamulin Monograph for Professionals". Drugs.com. Archived from the original on 6 August 2020. Retrieved 21 July 2021.
- ^ a b "Altargo". Archived from the original on 9 April 2021. Retrieved 21 July 2021.
- ^ "Retapamulin Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 21 July 2021.
- ^ Hartman-Adams, Holly; Banvard, Christine; Juckett, Gregory (15 August 2014). "Impetigo: Diagnosis and Treatment". American Family Physician. 90 (4): 229–235. ISSN 0002-838X. Archived from the original on 24 May 2021. Retrieved 21 July 2021.